Managing Cranial Nerve Impairment in Multiple Myeloma Following Cilta-cel

Commentary
Video

Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.

It is critical to quickly conduct neurological workups to verify cases of cranial nerve palsy (CNP) in patients with multiple myeloma who receive treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti), according to Leslie Bennett, MSN, RN.

Bennett, a nurse coordinator at Stanford Healthcare, spoke with CancerNetwork® during the 2024 Oncology Nursing Society Conference about the importance of clinicians and nurse providers preparing for CNP in patients who undergo treatment with cilta-cel for multiple myeloma. She stated that nurses, in particular, should be educated on this toxicity so that they can identify and subsequently mitigate symptoms in patients who may experience CNP before, during, or after CAR T-cell infusion.

In a poster presentation given at the conference, Bennett highlighted findings on CNP outcomes from the phase 1/2 CARTITUDE-1 trial (NCT03548207), phase 2 CARTITUDE-2 trial (NCT04133636), and phase 3 CARTITUDE-4 trial (NCT04181827), which assessed the use of cilta-cel in various populations with multiple myeloma. Across these trials, patients had CNP onset at a median of approximately 3 weeks following treatment with cilta-cel. Additionally, most cases of CNP affected male patients and were typically low-grade.

Transcript:

[Cranial nerve impairments are] something that we do discuss in the new patient visit, when the patients are being consented, and when we’re talking about all the neurological toxicities, including the fact that they could have the cranial nerve VII impairment causing the palsy typically during delayed onset.

It’s good for nurses, specifically, to be educated on this so that they can prepare their patients and the caregivers before, during, and after their CAR T infusions so that they can find the signs and symptoms and adequately get them addressed. It’s important to have a rapid neurological workup to ensure that what indeed is happening is a nerve palsy and not another neurological [adverse] effect from the CAR T therapy.

Reference

Bennett L, Kruyswijk S, Sidana S, et al. Incidence and management of cranial nerve impairments in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Presented at the 49th Annual Oncology Nursing Society Conference; April 24-28, 2024; Washington, DC.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content
"Our preliminary results showed that the efficacy of fruquintinib combined with capecitabine is promising with well tolerance as maintenance therapy in RAS/BRAF wild-type mCRC,” according to lead study author, Kai Ou.

Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

Courtney Flaherty
May 9th 2025
Article

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

71 Beyond the Surface: Suspicious Nipple Lesions

71 Beyond the Surface: Suspicious Nipple Lesions

Margarita Riojas Barrett;Logan Healy;Neil Farnsworth;Elizabeth Bonefas;Alastair Thompson;Stacey Carter
May 8th 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes

72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes

Hudhaifah Shaker;Kristin Manor;Shaneel Shah;Emma Barrett;Megan Bydder;Rajiv Dave;James C. Harvey, MD;Cliona Kirwan;Benjamin Baker
May 7th 2025
Article
Developers designed ISB 2001 to target BCMA and CD38 expressed on myeloma cells as well as CD3 on T cells.

FDA Gives Fast-Track Designation to ISB 2001 in Relapsed/Refractory Myeloma

Russ Conroy
May 7th 2025
Article

Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.